Pharmaceuticals News

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash...

- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly...

WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

Aggregated presentation by day and by market Weekly report on share repurchases from 04th August to 05th August 2026       Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of...

Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 4 août au 5 août 2026       Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de...

Company announcement no. 29 – 2610 August 2026 NTG Nordic Transport Group publishes interim report for H1 2026The interim report for H1 2026 is enclosed. In connection with publication of the...

Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or...

Six new Genome BC supported projects use integrated genomic and health data to explore earlier diagnosis, personalized care and better outcomes.

NeOnc Technologies (NASDAQ:NTHI) is scheduled to unveil topline Phase 2a results for NEO100 on Wednesday, August 12